Astrix™ aspirin capsules are the only enteric coated pelletised form of low-dose aspirin on the market, and are used for the same indication as Astrix™ tablets. Their enteric coat allows the release of aspirin to be delayed, until the pellets reach the small intestine, thereby reducing the risk of gastric ulceration that may be experienced with longer term use of immediate release aspirin.
Astrix™ capsules and/or tablets are currently licensed and sold in Australia, Hong Kong, Korea, Mauritius, Singapore and Sri Lanka. Opportunities remain for licensing in a significant number of international territories.
Astrix™ aspirin tablets are an immediate release low-dose form of aspirin indicated for inhibition of platelet aggregation to help prevent heart attack and stroke in patients with known cardiovascular and cerebrovascular disease.
Mayne Pharma offers Astrix™ capsules and tablets on the Pharmaceutical Benefits Scheme (PBS) in Australia.
Your doctor will advise you whether using Astrix™ capsules or tablets as part of an overall program to manage the risk of heart attack or stroke is suitable for you. Always read the label. Use only as directed. If symptoms persist see your doctor.